Who is sponsoring NCT02064036?

NCT02064036 is sponsored by University of California, Davis.

What drugs are being tested in NCT02064036?

Interventions in NCT02064036: Stereotactic Radiosurgical Boost, Casodex, Leuprolide.

What condition does NCT02064036 study?

NCT02064036 studies Adenocarcinoma of the Prostate.

Is NCT02064036 still recruiting?

NCT02064036 is currently completed. Last updated 18 October 2022.

Last reviewed 2022-10-18 · How we verify

NCT02064036: CCRO025

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate

Completed Phase 1 Last updated 18 October 2022

What this trial tests

Phase 1 trial testing Stereotactic Radiosurgical Boost in Adenocarcinoma of the Prostate in 17 participants. Completed in 29 October 2021.

Timeline

6 June 2013

Primary endpoint
3 December 2020

29 October 2021

Quick facts

Lead sponsor	University of California, Davis
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	17
Start date	6 June 2013
Primary completion	3 December 2020
Estimated completion	29 October 2021
Sites	1 location across United States

Drugs / interventions tested

Stereotactic Radiosurgical Boost
Casodex — full drug profile →
Leuprolide (leuprolide) — full drug profile →

Conditions studied

Adenocarcinoma of the Prostate — all drugs for Adenocarcinoma of the Prostate →

Sponsor

University of California, Davis

Who can join

18 and older, male only, with Adenocarcinoma of the Prostate. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We hypothesize that Stereotactic Body Radiotherapy Boost (SBRT) as a boost to the prostate following whole pelvic intensity modulated radiotherapy (IMRT) can be delivered effectively and safely in a population of men with unfavorable intermediate and high risk localized prostate cancer. Our primary objective is to assess the feasibility and safety of a treatment strategy incorporating whole pelvic IMRT followed by an SBRT boost to the prostate with neoadjuvant, concurrent, and adjuvant androgen deprivation for a total of 28 months for men with unfavorable intermediate or high risk localized prostate cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Virtual HDR Boost for Prostate Cancer: Rebooting a Classic Treatment Using Modern Tech.
Wegener E, Samuels J, Sidhom M, Trada Y, et al · · 2023 · cited 1× · PMID 37046680 · DOI 10.3390/cancers15072018

Verify or expand the search:

Other recruiting trials for Adenocarcinoma of the Prostate

Currently open trials in the same condition.

NCT04909294 — Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients · NA · active not recruiting
NCT02176902 — Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer · NA · active not recruiting
NCT02023463 — Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer · Phase 1 · active not recruiting
NCT02296229 — Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer · NA · active not recruiting
NCT01655836 — High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer · Phase 1 · active not recruiting

Other University of California, Davis trials

Trials by the same sponsor.

NCT07024498 — Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment · NA · not yet recruiting
NCT07322133 — Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE) · Phase 4 · recruiting
NCT07384767 — Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing · Phase 2 · not yet recruiting
NCT07267494 — Image-Guided Herniorrhaphy Study · NA · not yet recruiting
NCT04614714 — Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants · Phase 2, PHASE3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02064036 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Davis
Last refreshed: 18 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02064036.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing